Clinical Trial Update: A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II open-label study of ipilimumab with GM-CSF in unresectable metastatic melanoma shows completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• ipilimumab (ipilimumab)

Snippet

Sponsor: University of Louisville | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-22